z-logo
Premium
Evidence that different regional sympathetic outflows vary in their sensitivity to the sympathoinhibitory actions of putative 5‐HT 1A and α 2 ‐adrenoceptor agonists in anaesthetized cats
Author(s) -
Ramage Andrew G.,
Wilkinson Steven J.
Publication year - 1989
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.1989.tb12660.x
Subject(s) - urapidil , splanchnic nerves , clonidine , moxonidine , sympatholytic , agonist , endocrinology , stimulation , chemistry , medicine , heart rate , blood pressure , receptor
1 An investigation was carried out to determine whether the centrally acting hypotensive drugs whose mechanisms of action are due either to activation of 5‐HT 1A receptors (flesinoxan, 8‐hydroxy‐2‐(di‐ n ‐propylamino)tetralin (8‐OH‐DPAT) and urapidil — also an α 1 ‐adrenoceptor antagonist) or to activation of α 2 ‐adrenoceptors (clonidine and moxonidine) cause differential sympathoinhibition. 2 Cats were anaesthetized with α‐chloralose and simultaneous recordings were made of whole cardiac, splanchnic and renal nerve activity, blood pressure and heart rate. Cumulative dose‐response (i.v.) curves were constructed in separate experiments for the above hypotensive agents on these parameters. 3 Renal nerve activity was found to be more sensitive to the sympathoinhibitory action of flesinoxan and 8‐OH‐DPAT when compared with cardiac nerve activity, whereas the reverse was observed for clonidine and moxonidine, cardiac being more sensitive than renal nerve activity. Splanchnic nerve activity was similarly affected by all drugs. Furthermore at the highest dose, all drugs tended to cause complete inhibition in all regional sympathetic nerve outflows. 4 Urapidil differed from all the above hypotensive drugs in that it caused a similar degree of sympathoinhibition in all sympathetic outflows at all doses. It is suggested that this may be due to the ability of urapidil to block central α 1 ‐adrenoceptors in addition to stimulation of 5‐HT 1A receptors.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here